JPX · 4519.T
Chugai Pharmaceutical Co., Ltd.
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
Loading market information…
JPX · 6849.T · JPY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Nihon Kohden Corporation’s quoted price sits in the upper half of its reported 52-week range, 14.27% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Nihon Kohden Corporation’s forward annual dividend is ¥32 per share, paid semi-annual. The forward yield is 1.98% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Nihon Kohden Corporation’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of ¥23. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nihon Kohden Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nihon Kohden Corporation, founded in 1951 and headquartered in Tokyo, Japan, is a global leader in healthcare technology. The company’s core operations encompass the research, development, manufacturing, sales, repair, and maintenance of advanced medical electronic equipment, serving markets across Japan, the Americas, Europe, Asia, and other international regions. Its extensive product range features sophisticated physiological measurement instruments, including electroencephalographs (EEGs), electrocardiographs (ECGs), evoked potential and electromyogram (EMG) systems, and polygraphs for cardiac catheterization laboratories. These offerings are integrated with diagnostic information systems and supported by essential consumables like recording papers, electrodes, and catheters, along with comprehensive maintenance services. Nihon Kohden also delivers cutting-edge patient monitoring solutions, such as central, bedside, and wireless monitors, alongside remote access software. These are seamlessly linked with clinical information systems and provided with associated disposables, including various electrodes and sensors. The company's therapeutic device portfolio includes critical equipment like defibrillators (including automated external defibrillators or AEDs), ventilators, pacemakers, anesthesia machines, and cochlear implants. Necessary consumables, such as AED pads and batteries, and related services are also supplied for these products. Furthermore, Nihon Kohden offers other specialized medical apparatus, such as hematology and clinical chemistry analyzers, ultrasound diagnostic equipment, and tools for research purposes. These are accompanied by consumables like test reagents, installation services, and ongoing maintenance. Beyond its primary focus on medical devices, the corporation also participates in insurance brokerage and technology licensing.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:37 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | May 13, 2025 | ¥36-18.08% vs estimate | ¥66.95B-1.79% vs estimate |
|---|
| Q3 2025 | Feb 5, 2025 | ¥46+92.27% vs estimate | ¥55.69B+2.11% vs estimate |
|---|
| Q2 2025 | Nov 7, 2024 | -¥2-106.83% vs estimate | ¥56.56B+2.92% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
¥2,405+¥36 (+1.5%)
Terumo Corporation’s quoted price sits in the upper half of its reported 52-week range, 10.58% below the high.
¥1,942+¥13 (+0.65%)
Sysmex Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.12% below the high.
¥3,668+¥31 (+0.85%)
Asahi Intecc Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 14.34% below the high.
¥11,410+¥390 (+3.54%)
Fukuda Denshi Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 8.65% below the high.
¥1,415+¥52 (+3.82%)
PHC Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 16.47% below the high.
¥418+¥2 (+0.48%)
Daiken Medical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 14.52% below the high.
¥1,727+¥6 (+0.35%)
Koken Ltd.’s quoted price sits in the lower half of its reported 52-week range, 24.32% below the high.
